Here is the design of a clinical trial:

Official Title: Comparison of Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Recurrence After Radical Prostatectomy (SHARE Trial): a Prospective, Randomized Controlled, Open-label, Multi Center, Superiority Study

Included conditions:
- Prostate Cancer
- Biochemical Recurrence
- Radiation
- Hypofractionation
- Dose Escalation
- Survival
- Radiation Toxicity
- Quality of Life

Study Armgroups:
- {'label': 'Hypofractionated', 'type': 'EXPERIMENTAL', 'description': '65 Gy/ 26 fractions (fraction size 2.5 Gy)', 'interventionNames': ['Radiation: Salvage radiation therapy']}
- {'label': 'Standard', 'type': 'ACTIVE_COMPARATOR', 'description': '66 Gy/ 33 fractions (fraction size 2 Gy)', 'interventionNames': ['Radiation: Salvage radiation therapy']}

Interventions:
- {'type': 'RADIATION', 'name': 'Salvage radiation therapy', 'description': 'Salvage radiation therapy for biochemical recurrence', 'armGroupLabels': ['Hypofractionated', 'Standard']}

Primary Outcomes:
- {'measure': 'Biochemical recurrence-free survival', 'description': 'PSA \\>0.2 ng/mLfollowed by a repeat measurement \\>0.2 ng/mL', 'timeFrame': '5 years'}

Please estimate the sample size based on the assumption: 
The trial assumes a minimum 5-year follow-up period, a 5% loss rate, 80% power, and a two-sided significance level (α) of 0.05.
Sample size considerations and statistical analysis
        The trial is powered to assess the superiority of HRT when compared with CRT. Power calculations are based on an absolute increase in bPFS of 15% (from 50 to 65%) at 5âyears following HRT compared with CRT according to the dose-response relationship described by King [9]. By postulating a minimum 5-year follow-up period and allowing 5% for loss, at least 144 patients per treatment arm (288 patients in total) are required, which achieves 80% power, with a two-sided Î± of 0.05. Subgroup analyses will be performed based on the risk group (intermediate vs. high-risk group), RT field size (prostate bed only vs. elective pelvic nodal irradiation), and use of ADT.
        Statistical analysis will be conducted according to the intention-to-treat approach. Survival data, PSA value, toxicity, and QoL information will be collected even though participants discontinue the planned treatment. Multiple imputation method will be used for handling missing data. The chi-square test and Studentâs t test will be used for categorical and continuous variables of patient characteristics, respectively. Time to biochemical progression will be calculated from the end of RT. The KaplanâMeier method will be applied to estimate bPFS curves, and the log-rank test will be used to compare the curves between the two study arms. The Kaplan-Meier method and log-rank test will be used to investigate DMFS and CSS. Acute toxicity outcomes and QoL will be estimated using the chi-square test, and late toxicity outcomes will be determined using the Kaplan-Meier method.